Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies

Chimeric antigen receptor T cells (CAR-Ts) constitute a novel therapeutic strategy for relapsed/refractory B-cell malignancies. With the extensive application of CAR-T therapy in clinical settings, CAR-T-associated toxicities have become increasingly apparent. However, information regarding the asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng, Wei, Guoqing, Liu, Yandan, Zhou, Houli, Wu, Wenjun, Yang, Luxin, Huang, He, Hu, Yongxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216343/
https://www.ncbi.nlm.nih.gov/pubmed/34144648
http://dx.doi.org/10.1177/09636897211025503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216343/
https://www.ncbi.nlm.nih.gov/pubmed/34144648
http://dx.doi.org/10.1177/09636897211025503

Ejemplares similares